NEW YORK (dpa-AFX Broker) - The research firm Jefferies has lowered its price target for Evonik from €15.10 to €12.20 and downgraded the stock from "hold" to "underperform." Analyst Chris Counihan cut his operating profit estimates for the specialty chemicals group by an average of 5 percent and is significantly more skeptical than the consensus. For 2027, the expert expects less than 20 percent of the recovery announced by the group, as he wrote in his reassessment on Monday afternoon. In this environment, the dividend will no longer be fully covered by cash inflows for some time. /rob/ag/zb
Publication of the original study: November 10, 2025 / 10:04 a.m. / Time zone not specified in study
Initial distribution of the original study: November 10, 2025 / 7:00 p.m. / Time zone not specified in study
-----------------------
dpa-AFX Broker – trader news from dpa-AFX
-----------------------
